Celdaz 500mg Injection

About

Celdaz 500mg Injection, likely containing gemcitabine, is a nucleoside analog antimetabolite used in the treatment of various solid tumors. It functions by inhibiting DNA synthesis and repair, leading to cell death. Once inside the cell, gemcitabine is phosphorylated to its active diphosphate and triphosphate forms. The diphosphate inhibits ribonucleotide reductase, reducing the deoxynucleotide pool necessary for DNA synthesis, while the triphosphate is incorporated into DNA, causing chain termination and apoptosis. This dual mechanism makes it a potent cytotoxic agent.

Its efficacy stems from its ability to disrupt the cell cycle, particularly in the S-phase, affecting rapidly dividing cancer cells. Celdaz is administered intravenously, and its pharmacokinetics involve rapid metabolism and renal excretion. Careful monitoring of hematological parameters is crucial due to its myelosuppressive potential. Its broad spectrum of activity makes it a valuable component in combination chemotherapy regimens for several advanced cancers.

Uses

• Pancreatic cancer
• Non-small cell lung cancer
• Breast cancer
• Ovarian cancer

Directions For Use

This medication is administered intravenously by a healthcare professional. Do not self-administer.

Benefits

• Effective against a range of solid tumors.
• Can be used as monotherapy or in combination.
• May improve survival rates in certain cancers.
• Helps reduce tumor size and disease progression.
• Relatively manageable side effect profile for chemotherapy.
• Offers a treatment option for advanced stages.

Side Effects

• Myelosuppression (neutropenia, thrombocytopenia, anemia)
• Nausea and vomiting
• Fever
• Rash
• Flu-like symptoms
• Elevated liver enzymes
• Proteinuria
• Peripheral edema
• Dyspnea
• Alopecia (hair loss)
• Stomatitis
• Renal dysfunction (rare)

Safety Measures

• Alcohol - Avoid alcohol as it may worsen gastrointestinal side effects or liver toxicity.
• Pregnancy - Celdaz is teratogenic; it should not be used during pregnancy. Women of childbearing potential must use effective contraception.
• Breastfeeding - Breastfeeding is contraindicated due to the potential for serious harm to the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary, and liver function should be closely monitored.
• Kidney - Use with caution in patients with renal impairment; dose adjustments may be required, and kidney function should be monitored.
• Lung - Monitor for signs of pulmonary toxicity, such as interstitial pneumonitis or acute respiratory distress syndrome, which can be severe.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.